Document:

Exhibit 10.1

 

December 29, 2022

 

Jennifer Cote

 

Dear Jennifer:

 

I am pleased to offer you the position of Interim Chief Financial Officer
and Treasurer of Harvard Bioscience, Inc. (the “Company”), effective as of January 1, 2023, reporting directly to me.
In connection with your appointment, we would like to adjust your compensation as follows:

 

	1.		Base Salary. Effective January 1, 2023, your annual base salary (your “Base
Salary”) will be $270,000.00, paid at a bi-weekly rate of $10,384.62.

 

	2.		Additional Cash Bonus. You will be eligible to receive a cash bonus (your “Cash
Bonus”) equal to twenty five percent (25%) of your Base Salary earned in 2023. The Cash bonus will be payable in quarterly
installments on March 31, June 30, September 30, and December 31, 2023. To receive your bonus, you must be employed by the Company on
the applicable payment date. The Cash Bonus is in addition to any cash incentive bonus that you may be eligible to receive for service
in 2023.

 

	3.		One-Time Equity Award. You will be eligible to receive a one-time equity award consisting
of time-based restricted stock units (RSUs) having a grant date value of $75,000 (the “One-Time RSU Award”) and vesting on
December 29, 2023. The One-Time Equity Award will be subject to valuation methodologies and other terms and conditions applicable to
other similarly situated executives of the Company. The One-Time Equity Award is subject to Compensation Committee approval, which we
intend to seek at the March meeting of the Compensation Committee. Your One-Time RSU Award will be in addition to any other equity awards
that you may be eligible to receive in 2023.

 

All your other current terms and conditions, covenants, and obligations, of your at-will employment,
including those in your April 28, 2022 offer letter, remain in full force and effect.

 

I congratulate you on this new opportunity and I am looking forward to your future success.

 

	
    HARVARD BIOSCIENCE, INC.

     

    /s/James W. Green

    Chairman and CEO

     

    Date: December 29, 2022
	
    JENNIFER COTE

     

    /s/Jennifer Cote

     

     

    Date: December 29, 2022Exhibit 10.2

 

 

 

Wednesday, April 27, 2022

Revised: Thursday, April 28, 2022

 

Jennifer S. Cote

Holliston, MA 01746

 

Sent via Email.

 

Dear Jennifer,

 

Harvard Bioscience “HBIO” is pleased to extend to you a full-time offer of employment
as Vice President, Finance based on the terms and subject to the conditions described below. I hope that you will find this new
position challenging and rewarding.

 

	Start Date	Monday, May 16, 2022
	Salary	
    Before all appropriate withholding deductions, your gross starting weekly salary will be $4,807.70
    paid every two weeks, which is the yearly equivalent of $250,000 annually.

     

    You are eligible to participate in the HBIO Annual Performance Plan. Your potential award is
    based on 25% of your salary earned during the incentive period (start date – December 31). The HBIO Compensation Committee will
    determine the measurement of the actual performance against goals in the HBIO Annual Performance Bonus Plan after the end of the year.

     

    Subject to the approval of the Board of Directors, you will receive an award of Harvard Bioscience
    restricted stock units (RSUs) equal to 50% of the starting annual salary.  The number of shares you receive will be based on the
    closing stock price of Harvard Bioscience on the date of the date of the approval of the award by the Company’s Board of Directors. 
    These awards will be subject to a vesting schedule of one-third per year, beginning with the first anniversary of the grant date. 
    The specific terms of the awards will be outlined in an individual award agreement which will be presented to you after the approval of
    the award.

     

	Other Benefits	You will also be eligible for all other customary benefits offered to our full-time employees.  These include group health, dental, life, disability insurance, the company 401(k) plan, and eleven (11) paid holidays.  As a senior leader in the organization, you will participate in a separate vacation plan which allows you to take time off as needed.

 

 

     

     

    

 

 

 

	Conditions of Employment	
    Your employment at HBIO will be “at will.” Either you or HBIO may terminate your
    employment, with or without cause. No definite term of employment is intended or offered.

     

    Your offer of employment at HBIO is conditional upon the following:

     

    ·       Your
information regarding academic degrees, certification, and criminal background must be verified as being accurate.

    ·       You
must sign HBIO standard confidentiality and noncompetition agreement and return the documents to Human Resources before your first day
of employment.

    ·       You
must sign the HBIO Code of Conduct and return the documents to Human Resources on your first day of employment.

    ·       Represent
that there are no contractual or other obligations with a former employer that would prohibit or interfere with your ability to work
for HBIO.

    ·       Under
the Immigration and Control Act (IRCA), you must be able to verify your identity and authorization to work as required by federal law.

    ·       You
confirm your formal acceptance by signing this letter and returning it to Lori Packer lpacker@harvardbioscience.com.

 

I sincerely hope this package will be acceptable. If this offer meets with
your understanding, please sign below, and return it to Lori Packer's attention by Monday, May 2, 2022. I look forward
to you becoming a full-time member of our team. Should you have any questions or desire additional information, please do not hesitate
to contact Lori or me.  

 

 

 

Sincerely,

 

/s/Michael Rossi

Chief Financial Officer

 

 

Accepted this 29th day of April 2022

 

/s/Jennifer CoteExhibit 10.4 

   

 BITNILE
Holdings, Inc. 

   

 Amended
and Restated Amendment To 

   

 Securities
Purchase Agreement 

   

 This amended and restated
amendment (the “Amendment”), dated as December 29, 2022 to the Securities Purchase Agreement dated December 16, 2022
(the “Agreement”), by and between ______________ (the “Majority Holder”) and BitNile Holdings,
Inc. (“NILE”). All capitalized terms in this Amendment and not defined herein shall have the meanings ascribed to
such terms in the Agreement. 

   

 WHEREAS, NILE and
the Majority Holder desire to amend the Agreement in certain respects to allow _________________ (“_____”) to invest
in the Notes. 

   

 WHEREAS, the Majority
Holder constitutes the “majority in interest” of the Investors as such term is used in the Agreement. 

   

 NOW, THEREFORE,
in consideration of the foregoing and intending to be legally bound hereby, the parties hereto agree as follows: 

   

 1.       The
definition of “Funding Amount” in Section I is hereby deleted and replaced in its entirely by the following: 

   

 “Funding Amount”
means an amount equal to Sixteen Million Eighty-One Thousand Eight Hundred Seventy Dollars and Fifty Cents ($16,081,870.50), consisting
of a cash payment of Thirteen Million Three Hundred Twenty-Two Thousand Nine Hundred Forty Dollars ($13,322,940), the forgiveness of
Nine Hundred Seventy-Two Thousand Fifty-Six Dollars ($972,056) owed to _____ by the Company for cashless exercise of warrants issued
to _____ on December 29, 2021 and a non-reimbursable expense allocation of One Million Seven Hundred Eighty-Six Thousand Eight Hundred
Seventy-Four Dollars and Fifty Cents ($1,786,874.50).” 

   

 2.       Section
2.1 is hereby deleted and replaced in its entirety by the following: 

   

 “2.1Purchase
and Sale of the Note. Subject to the terms and conditions set forth herein, at the Closing, the Company shall issue and sell to the
Investors, and the Investors shall purchase from the Company, original issuance discount senior secured promissory notes in the form
attached hereto as Exhibit B (the “Note”), in the aggregate principal amount of Seventeen Million Five Hundred Eleven
Thousand Three Hundred Seventy Dollars and Ten Cents ($17,511,370.10), subject to adjustment as set forth in the Note (the “Principal
Amount”) in exchange for the Funding Amount.” 

   

 3.       Section
2.2 is hereby deleted and replaced in its entirety by the following: 

   

 “2.2Closing.
The closing hereunder, including payment for and delivery of the Note, shall take place remotely via the exchange of documents and signatures,
no later than ten (10) Business Days following the execution and delivery of this Agreement, subject to satisfaction or waiver of the
conditions set forth in Section 6, or at such other time and place as the Company and the Investor agree upon, orally or in writing (the
“Closing,” and the date of the Closing being the “Closing Date”). On the Closing Date, (i) the
Investor shall pay the Funding Amount to the Company by wire transfer of immediately available funds in accordance with the Company’s
written wire instructions and (ii) the Company shall issue to the Investor a Note in the Principal Amount, duly executed on behalf of
the Company and registered in the name of the Investor or its designee. Notwithstanding anything else to the foregoing, the sale of the
Notes may be made in one or more Closings and on one or more Closing Dates.” 

   

    	 	 	 

    	 

    

   

 4.       The
Company and the Majority Holder acknowledge and agree that the initial Closing occurred on December 16, 2022, whereby the Majority Holder
purchased a Note in the principal amount of Fourteen Million Seven Hundred Thousand Dollars ($14,700,000) in exchange for the funding
amount of Thirteen Million Five Hundred Thousand Dollars ($13,500,000), consisting of a cash payment of Twelve Million Dollars ($12,000,000)
and a non-reimbursable expense allocation of One Million Five Hundred Thousand Dollars ($1,500,000). 

   

 5.       This
Amendment shall be binding on the Holder and all of its successors, heirs, personal representatives and assigns and permitted transferees. 

   

 6.       Except
as amended hereby, the Agreement shall remain unmodified and is hereby ratified in all respects. 

   

 7.       This
Amendment may be executed and delivered (including by electronic or facsimile transmission) in one or more counterparts, and by the different
parties hereto in separate counterparts, each of which when executed and delivered shall be deemed to be an original but all of which
taken together shall constitute one and the same agreement. 

   

 Agreed this 29nd
day of December, 2022. 

   

   

	 BITNILE
    HOLDINGS, INC. 	   	   
	   	   	   	   	   
	   	   	   	   	   
	 By: 	   	   	 By: 	   
	   	 William B. Horne 	   	   	   
	   	 Chief Executive Officer 	   	   	   

   

   

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]